Ingevity (NYSE:NGVT – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Ingevity in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $80.00.
Get Our Latest Stock Analysis on NGVT
Ingevity Stock Performance
Ingevity (NYSE:NGVT – Get Free Report) last released its earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share for the quarter, topping analysts’ consensus estimates of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, equities research analysts forecast that Ingevity will post 5.05 EPS for the current fiscal year.
Insider Buying and Selling at Ingevity
In related news, SVP Terrance M. Dyer sold 496 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the sale, the senior vice president owned 7,202 shares in the company, valued at $493,264.98. The trade was a 6.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.88% of the company’s stock.
Hedge Funds Weigh In On Ingevity
Several hedge funds have recently added to or reduced their stakes in the stock. Global Retirement Partners LLC purchased a new stake in shares of Ingevity during the 4th quarter worth approximately $27,000. Meeder Asset Management Inc. purchased a new position in shares of Ingevity in the 4th quarter valued at $33,000. Kestra Advisory Services LLC purchased a new position in shares of Ingevity in the 4th quarter valued at $47,000. Geneos Wealth Management Inc. raised its stake in Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after acquiring an additional 387 shares in the last quarter. Finally, Harbor Investment Advisory LLC acquired a new stake in Ingevity during the 2nd quarter worth $71,000. 91.59% of the stock is currently owned by hedge funds and other institutional investors.
About Ingevity
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Stories
- Five stocks we like better than Ingevity
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
